Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

Evolusion owns the 845 patent, titled “Method and Device for Converting Firearm with Detachable Magazine to a Firearm with Fixed Magazine.” Evolusion sued Juggernaut, alleging infringement of several claims. The district court granted Juggernaut summary judgment of non-infringement, reasoning that the term “magazine catch bar” in the asserted claims excluded a factory-installed magazine catch bar. The court held that claim construction concededly precludes literal infringement because Juggernaut’s products use the factory-installed magazine catch bar. The court also determined that Juggernaut did not infringe under the doctrine of equivalents. The Federal Circuit reversed, holding that the term “magazine catch bar” in the asserted claims includes a factory-installed magazine catch bar.Evolusion also sued Juggernaut for infringement, based on Juggernaut’s manufacture and sale of its “Hellfighter Mod Kits,” which convert a firearm with a detachable magazine into a firearm with a fixed magazine. The court determined that no construction was needed of the term “upper tension bar,” that “magazine catch bar” excluded a factory-installed (OEM) magazine catch bar, and that under that construction, Juggernaut cannot infringe under the doctrine of equivalents. The Federal Circuit again reversed, construing the term “magazine catch bar” “according to its ordinary meaning,” which includes a factory-installed magazine catch bar. View "Evolusion Concepts, Inc. v. Hoc Events, Inc." on Justia Law

Breland served in the Army in Vietnam, 1965-1968, and was exposed to Agent Orange. In 2006, Breland was diagnosed with carcinoma of the tongue; he completed his treatments in January 2007. The VA Regional Office denied Breland’s claim for service connection. A January 2008 biopsy revealed the recurrence of Breland’s tongue cancer. He underwent surgery. Breland filed a Notice of Disagreement. In 2010, a VA examiner note Breland’s complaint of continuing dry mouth, found no recurrence of Breland’s cancer, and concluded that the condition was “less likely related” to herbicide exposure. Breland’s claim was again denied.In 2015, Breland submitted a medical opinion tying his tongue cancer to Agent Orange exposure and retroactively granted service connection, with a 100% rating for December 2006-August 2007, and a non-compensable rating, based on Breland’s inactive disease. Following a September 2017 VA examination, the Regional Office granted service connection for certain residual conditions and determined that a 100% rating for Breland’s tongue cancer was warranted retroactively for an additional eight-month period. The Board of Veterans’ Appeals and Federal Circuit upheld those determinations. Diagnostic Code 7343 does not require the VA to continue a 100% disability rating until it performs a “mandatory VA examination” six months following treatment when the disability rating is assigned retroactively after the six-month period has passed. Breland has been and is fairly compensated based on the actual state of his health. View "Breland v. McDonough" on Justia Law

B.W., a two-year-old in good health, experienced immune thrombocytopenic purpura after receiving his measles, mumps, and rubella vaccine. Later blood tests showed his condition had resolved. More than six months after he was first diagnosed, B.W. presented with bruising, a possible symptom of immune thrombocytopenic purpura, but blood tests showed the condition had not recurred. In a suit under the National Childhood Vaccine Injury Act of 1986, the Claims Court ruled in favor of B.W., holding that those blood tests, occurring more than six months after his initial diagnosis, were “residual effects” of B.W.’s vaccine injury that satisfied the severity requirement of 42 U.S.C. 300aa-11(c)(1)(D).The Federal Circuit reversed. A residual effect must be a change within the patient that is caused by the vaccine injury. B.W.’s later bruising was not caused by his vaccine injury, and his tests did not reveal, constitute, or cause any somatic change. Tests revealed B.W. had no lingering symptoms or recurrence of thrombocytopenic purpura. There was no argument that the testing itself was detrimental to B.W.’s health such that it might qualify under section 300aa-11(c)(1)(D)(i) as a “residual effect” or a “complication” of thrombocytopenic purpura. View "Wright v. Secretary of Health and Human Services" on Justia Law

The Browns, U.S. citizens, lived in Australia while Mr. Brown worked for Raytheon. The IRS received the Browns' amended returns for 2015 and 2017, claiming the Foreign Earned Income Exclusion, signed by attorney Castro, but not accompanied by powers of attorney. The Browns' second amended return for 2015, again signed by Castro, also did not append any powers of attorney. The IRS disallowed the refund claims, indicating that "as an employee of Raytheon . . . [Brown] may have entered into a closing agreement . . . irrevocably waiving” Browns’ rights to claim the Exclusion under section 911(a).The Browns filed a refund suit under 26 U.S.C. 6532 and 7422(a). The government argued that the Browns had not “duly filed” their administrative refund claims in accordance with section 7422(a) because they had not personally signed and verified their amended returns or properly authorized an agent to execute them. The Browns responded that the IRS had waived those requirements by processing their claims despite the defects and that the requirements were waivable regulatory conditions. The Claims Court dismissed the suit for lack of subject matter jurisdiction. The Federal Circuit affirmed. The Claims Court had jurisdiction; the “duly filed” requirement is more akin to a claims-processing rule than a jurisdictional requirement. However, the Browns did not meet that requirement, which derives from statute and cannot be waived by the IRS, nor did the IRS waive the requirement. View "Brown v. United Statesx" on Justia Law

Novartis markets a 0.5 mg daily dose of fingolimod hydrochloride under the brand name Gilenya. The medication is used to treat relapsing-remitting multiple sclerosis, a debilitating immune-mediated demyelinating disease in which the immune system attacks the myelin coating the nerves in the central nervous system. Most MS patients initially present as RRMS patients, but many eventually develop a secondary progressive form of MS, causing them to experience growing disability. There is currently no cure for MS. The disease is managed by reducing or preventing relapses and thereby slowing disability.HEC filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Gilenya. Novartis sued, alleging that HEC’s ANDA infringes all claims of the 405 patent. The Federal Circuit affirmed a holding that the patent is not invalid and that HEC’s ANDA infringes. The 405 claims do not fail the written description requirement of 35 U.S.C. 112(a). The district court did not clearly err in finding that a skilled artisan would read the 405 patent’s disclosure to describe the “absent an immediately preceding loading dose” negative limitation. View "Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc." on Justia Law

The Army requested bids for helicopter flight training and awarded the contract to L3. In a bid-protest action filed by disappointed bidder S3, the Claims Court set aside the award. After reevaluation of the bids, the Army awarded the contract to CAE. S3 filed another bid protest.The Claims Court rejected most of S3’s arguments but agreed that the assignment by the Army’s source selection authority (SSA) of a certain “strength” to CAE was irrational because that strength, which purported to provide a “significant cost savings benefit,” would result in only small and unpredictable savings, if any. Nevertheless, the Claims Court upheld the award, finding no prejudice to S3 from the identified error. The Claims Court observed that the erroneously found strength had been treated as falling within a non-price-factor category for which CAE’s proposal had been “clearly superior,” an assessment that would not be altered by the loss of a strength for which the only possible benefit could be monetary; when explicitly comparing the added benefits of the CAE proposal with its higher price in the best-value tradeoff analysis, the SSA had not made any adjustment to CAE’s price based on a cost-saving from the strength.The Federal Circuit affirmed, rejecting an argument that there is a presumption of prejudice whenever the Claims Court determines that the agency acted irrationally in making an award decision and finding no clear error in the determination that there was no prejudice. View "System Studies & Simulation, Inc. v. United States" on Justia Law

Qualcomm’s patent, titled “Direct Scatter Loading of Executable Software Image from a Primary Processor to One or More Secondary Processor in a Multi-Processor System,” addresses a system with multiple processors, each of which must execute its own “boot code” to play its operational role in the system. Such code must be stored in non-volatile memory (e.g., flash memory or read-only memory) and the boot code generally must be transferred to its corresponding processor’s volatile memory in order to be executed by that processor. The patent describes systems, methods, and apparatuses for efficiently retrieving an executable software image from the first processor’s non-volatile memory and loading it for use by the second processor.In inter partes review, the Patent Trial and Appeal Board held that Intel had proved several claims unpatentable but not others. The Federal Circuit vacated in part, first holding that Intel adequately demonstrated Article III standing. The Board failed to tie its construction of the phrase “hardware buffer” to the actual invention described in the specification; the court remanded as to 10 claims for new construction. The court also vacated as to two claims that are in means-plus-function format. The Board failed to determine for itself whether there is sufficient corresponding structure in the specification to support those claims and whether it can resolve the patentability challenges despite the (potential) indefiniteness of those claims. View "Intel Corp. v. Qualcomm, Inc." on Justia Law

Dr. Metzinger brought an Equal Pay Act (EPA) suit against her employer, the VA, in the Eastern District of Louisiana, alleging that the government violated 29 U.S.C. 206(d), by paying her less than her male subordinates. She sought over $10,000 in damages. The government argued that the Court of Federal Claims had exclusive subject-matter jurisdiction over EPA claims against the government for over $10,000. In the alternative to dismissal, the government requested that the district court transfer Metzinger’s EPA claim to the Claims Court under 28 U.S.C. 1631. Metzinger opposed dismissal but allowed that if the district court concluded that it lacked jurisdiction, it should transfer the EPA claim. The district court agreed that it lacked subject-matter jurisdiction and transferred Metzinger’s EPA claim to the Claims Court under 28 U.S.C. 1631.Metzinger appealed to both the Fifth and Federal Circuits. The Fifth Circuit summarily dismissed. In a joint filing, the government reversed course, agreeing with Metzinger that the district court possessed jurisdiction. The Federal Circuit affirmed the transfer to the Claims Court. Precedent dictates that district courts lack subject-matter jurisdiction over EPA claims against the government for over $10,000. View "Metzinger v. Department of Veterans Affairs" on Justia Law

Tolliver had a contract with the United States under which Tolliver was obliged to write technical manuals for government-used equipment. The government was obliged to supply Tolliver information relevant to that task. When the government failed to obtain and therefore failed to supply that information, the parties modified the contract. Tolliver ultimately produced the manuals. After the modification, however, a third party sued Tolliver in the name of the government under the False Claims Act, alleging that Tolliver had made a false certification of compliance with the original contract. The government, rather than intervening in the qui tam case and then dismissing it, allowed it to proceed. With evidentiary help from the government, Tolliver prevailed after incurring substantial legal fees.The contracting officer denied Tolliver's claim under the Contract Disputes Act, 41 U.S.C. 7101, for an “equitable adjustment” for reimbursement of “allowable legal fees.” The Claims Court entered judgment for Tolliver, concluding that the United States had breached an implied warranty of performance. The Federal Circuit vacated. Because Tolliver never submitted a claim of breach of that warranty to the contracting officer, the Claims Court lacked jurisdiction to adjudicate such a claim. The claim that Tolliver presented to the contracting officer was, on its face, based on legal fees, not on a breach of the implied warranty of performance. View "Tolliver Group, Inc. v. United States" on Justia Law

Former and current Drug Enforcement Agency (DEA) employees were relocated to Puerto Rico or the U.S. Virgin Islands at the DEA’s request for two to five years. Each received a one-time relocation incentive bonus under 5 U.S.C. 5753(b), which provides that “[t]he Office of Personnel Management may authorize the head of an agency to pay a [relocation incentive] bonus” to an individual who relocates to accept a position. Each bonus was equivalent to 25% of each employee’s yearly salary. The employees allege they are entitled to a relocation incentive bonus for each year of their relocation, rather than the one-time bonus they received.The Federal Circuit affirmed the Claims Court’s dismissal of that claim, for lack of subject matter jurisdiction. The claim was not based on a statute or regulations that are money mandating, as required for jurisdiction under the Tucker Act, 28 U.S.C. 1491(a)(1). The statute and implementing regulations use discretionary language. View "Bell v. United States" on Justia Law